Kojima Motohiro, Ishii Genichiro, Atsumi Naho, Fujii Satoshi, Saito Norio, Ochiai Atsushi
Pathology Division, Research Center for Innovative Oncology, 6-3-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
Cancer Sci. 2008 Aug;99(8):1578-83. doi: 10.1111/j.1349-7006.2008.00849.x.
CD133 has been reported to be a cancer-initiating cell marker in colorectal carcinoma. The objective of this study was to evaluate the frequency of CD133 expression in colorectal cancer, the distribution of CD133-positive cancer cells, and their relationship to clinicopathological features, including survival. An immunohistochemical examination of CD133 expression and a clinicopathological analysis were performed in the 189 consecutive colorectal cancer patients. CD133 expression was seen at the luminal surface of cancer glands mainly with cribriform features. Expression was detected in only 29 of the 189 tumors (15.3%). Of these, 21 tumors (11.1%) showed CD133 overexpression. All 21 tumors with CD133 overexpression were diagnosed as well- or moderately-differentiated adenocarcinoma. There was no difference in the distribution of CD133 expressing cells between the invasive area and surface area. Although there was no difference in recurrence-free survival between patients with CD133 overexpression and without, the patients with CD133 overexpression had significantly poorer overall survival (P = 0.03). CD133 overexpression is a risk factor for poorer overall survival in patients with well- and moderately-differentiated adenocarcinoma. Expression of this cancer-initiating cell marker may vary with the histological type of the cancer, and further investigation of the relationship between its expression and clinicopathological features may be necessary.
据报道，CD133是结直肠癌中的一种癌症起始细胞标志物。本研究的目的是评估CD133在结直肠癌中的表达频率、CD133阳性癌细胞的分布及其与临床病理特征（包括生存率）的关系。对189例连续的结直肠癌患者进行了CD133表达的免疫组织化学检查和临床病理分析。CD133表达主要见于具有筛状特征的癌腺管腔表面。在189例肿瘤中，仅29例（15.3%）检测到表达。其中，21例肿瘤（11.1%）显示CD133过表达。所有21例CD133过表达的肿瘤均被诊断为高分化或中分化腺癌。CD133表达细胞在浸润区和表面区的分布无差异。虽然CD133过表达患者和未过表达患者的无复发生存率无差异，但CD133过表达患者的总生存率显著较差（P = 0.03）。CD133过表达是高分化和中分化腺癌患者总生存率较差的危险因素。这种癌症起始细胞标志物的表达可能因癌症的组织学类型而异，可能有必要进一步研究其表达与临床病理特征之间的关系。
